Document:

Exhibit 10.60

 

Coronado
Biosciences, Inc.

2013 Stock Incentive Plan

Award Agreement

(Incentive Stock Option or Non-Qualified Stock Option)

 

Pursuant to this Award
Agreement, which includes your Stock Option Grant Notice (“Grant Notice”), Coronado Biosciences, Inc.
(the “Company”) has granted you an option under its 2013 Stock Incentive Plan (the “Plan”)
to purchase the number of shares of the Company’s Common Stock indicated in your Grant Notice at the exercise price indicated
in your Grant Notice. Defined terms not explicitly defined in this Award Agreement but defined in the Plan shall have the same
definitions as in the Plan.

 

The details of your
option are as follows.

 

1.            Vesting.
Subject to the limitations contained herein, your option will vest as provided in your Grant Notice, provided that vesting will
cease upon the termination of your Continuous Service.

 

2.            Number
of Shares and Exercise Price. The number of shares of Common Stock subject to your Option and your exercise price per
share referenced in your Grant Notice may be adjusted from time to time for changes in the Company’s capitalization as provided
in Section 10(a) of the Plan.

 

3.            Exercise
Restriction for Non-Exempt Employees. In the event that you are an Employee eligible for overtime compensation under
the Fair Labor Standards Act of 1938, as amended (i.e., a “Non-Exempt Employee”), you may not
exercise your Option until you have completed at least six (6) months of Continuous Service measured from the Date of Grant specified
in your Grant Notice, notwithstanding any other provision of your Option.

 

4.            Exercise
prior to Vesting (“Early Exercise”). If permitted in your Grant Notice (i.e., the “Exercise
Schedule” indicates “Early Exercise Permitted”) and subject to the provisions of your Option, you may elect at
any time that is both (i) during the period of your Continuous Service and (ii) during the term of your Option, to exercise all
or part of your option, including the unvested portion of your Option; provided, however, that:

 

(a)        a partial
exercise of your Option shall be deemed to cover first vested shares of Common Stock and then the earliest vesting installment
of unvested shares of Common Stock;

 

(b)        any shares
of Common Stock so purchased from installments that have not vested as of the date of exercise shall be subject to a repurchase
right in favor of the Company or a Related Entity as described in an early exercise stock purchase agreement;

 

(c)       you shall
enter into an early exercise stock purchase agreement with a vesting schedule that will result in the same vesting as if no early
exercise had occurred; and

 

    	 

    	 

    

 

(d)        if your
option is an Incentive Stock Option, then, to the extent that the aggregate Fair Market Value (determined at the time of grant)
of the shares of Common Stock with respect to which your Option plus all other Incentive Stock Options you hold are exercisable
for the first time by you during any calendar year (under all plans of the Company and its Affiliates) exceeds one hundred thousand
dollars ($100,000), your Option(s) or portions thereof that exceed such limit (according to the order in which they were granted)
shall be treated as Non-Qualified Stock Options.

 

5.            Method
of Payment. Payment of the exercise price is due in full upon exercise of all or any part of your option. You may elect
to make payment of the exercise price in cash or by check or in any other manner permitted by your Grant Notice,
which may include one or more of the following:

 

(a)         provided
that at the time of exercise the Common Stock is publicly traded, pursuant to a program developed under Regulation T as promulgated
by the Federal Reserve Board that, prior to the issuance of Common Stock, results in either the receipt of cash (or check) by the
Company or the receipt of irrevocable instructions to pay the aggregate exercise price to the Company from the sales proceeds;

 

(b)         provided
that at the time of exercise the Common Stock is publicly traded, by delivery to the Company (either by actual delivery or attestation)
of already-owned shares of Common Stock that are owned free and clear of any liens, claims, encumbrances or security interests,
and that are valued at Fair Market Value on the date of exercise; notwithstanding the foregoing, you may not exercise your Option
by tender to the Company of Common Stock to the extent such tender would violate the provisions of any law, regulation or agreement
restricting the redemption of the Company’s stock;

 

(c)          if your
Option is a Non-Qualified Stock Option, by a “net exercise” arrangement pursuant to which the Company will reduce the
number of shares of Common Stock issued upon exercise of your Option by the largest whole number of shares with a Fair Market Value
that does not exceed the aggregate exercise price; provided, however, that the Company shall accept a cash or other payment
from you to the extent of any remaining balance of the aggregate exercise price not satisfied by such reduction in the number of
whole shares to be issued; provided further, however, that shares of Common Stock will no longer be outstanding under your
Option and will not be exercisable thereafter to the extent that (1) shares are used to pay the exercise price pursuant to the
“net exercise,” (2) shares are delivered to you as a result of such exercise, and (3) shares are withheld to satisfy
tax withholding obligations; or

 

(d)          pursuant
to the following promissory note alternative:

 

(i)          not
less than one hundred percent (100%) of the aggregate exercise price, plus accrued interest, shall be due four (4) years from
date of exercise or, at the Company’s election, upon termination of your Continuous Service;

 

(ii)        interest
shall be compounded at least annually and shall be charged at the minimum rate of interest necessary to avoid (1) the treatment
as interest, under any applicable provisions of the Code, of any amounts other than amounts stated to be interest under the deferred
payment arrangement and (2) the classification of your option as a liability for financial accounting purposes; and

 

    	2

    	 

    

 

(iii)       in
order to elect the promissory note alternative, you must, as a part of your written notice of exercise, give notice of the election
of this payment alternative and, in order to secure the payment of the deferred exercise price to the Company hereunder, if the
Company so requests, you must tender to the Company a promissory note and a pledge agreement covering the purchased shares of
Common Stock, both in form and substance satisfactory to the Company, or such other or additional documentation as the Company
may request.

 

6.            Whole
Shares. You may exercise your option only for whole shares of Common Stock.

 

7.            Securities
Law Compliance. Notwithstanding anything to the contrary contained herein, you may not exercise your option unless the
shares of Common Stock issuable upon such exercise are then registered under the Securities Act of 1933, as amended (the “Securities
Act”) or, if such shares of Common Stock are not then so registered, the Company has determined that such exercise
and issuance would be exempt from the registration requirements of the Securities Act. The exercise of your Option also must comply
with other applicable laws and regulations governing your option, and you may not exercise your Option if the Company determines
that such exercise would not be in material compliance with such laws and regulations.

 

8.            Term.
You may not exercise your Option before the commencement of its term or after its term expires. The term of your Option commences
on the Date of Grant and expires upon the earliest of the following:

 

(a)         immediately
upon the termination of your Continuous Service for Cause;

 

(b)         three (3)
months after the termination of your Continuous Service for any reason other than Cause, Disability or death; provided however,
that if during any part of such three (3) month period you may not exercise your Option solely because of the condition
set forth in the preceding section relating to “Securities Law Compliance,” your option shall not expire until the
earlier of the Expiration Date indicated in your Grant Notice or until it shall have been exercisable for an aggregate period of
three (3) months after the termination of your Continuous Service; provided, further, that in the event you die within three
(3) months after the termination of your Continuous Service for any reason other than Cause or Disability, your Option shall not
expire until the earlier of the Expiration Date or until it shall have been exercisable for an aggregate period of twelve (12)
months after your death;

 

(c)         twelve
(12) months after the termination of your Continuous Service due to your Disability; provided, however, that in the event
you die within such twelve (12) month period after the termination of your Continuous Service due to your Disability, your option
shall not expire until the earlier of the Expiration Date or until it shall have been exercisable for an aggregate period of twelve
(12) months after your death;

 

    	3

    	 

    

 

(d)         twelve
(12) months after the termination of your Continuous Service due to your death;

 

(e)         the Expiration
Date indicated in your Grant Notice; or

 

(f)         the day
before the tenth (10th) anniversary of the Date of Grant; provided, however, in the case of an Incentive Stock Option granted
to you, if at the time the Option is granted, you own stock representing more than ten percent (10%) of the voting power of all
classes of stock of the Company or any Parent or Subsidiary of the Company, the Option shall expire the day before the fifth (5th)
anniversary of the Date of Grant.

 

If your Option is an
Incentive Stock Option, note that to obtain the federal income tax advantages associated with an Incentive Stock Option, the Code
requires that at all times beginning on the date of grant of your Option and ending on the day three (3) months before the date
of your Option’s exercise, you must be an employee of the Company or an Affiliate, except in the event of your death or your
permanent and total disability, as defined in Section 22(e)(3) of the Code. (The definition of disability in Section 22(e)(3) of
the Code may be different from the definition of the Disability under the Plan). The Company has provided for extended exercisability
of your Option under certain circumstances for your benefit but cannot guarantee that your Option will necessarily be treated as
an Incentive Stock Option if you continue to provide services to the Company or an Affiliate as a Consultant or Director after
your employment terminates or if you otherwise exercise your Option more than three (3) months after the date your employment with
the Company or an Affiliate terminates.

 

9.            Exercise.

 

(a)         You may
exercise the vested portion of your Option (and the unvested portion of your Option if your Grant Notice so permits) during its
term by delivering a Notice of Exercise (in a form designated by the Company), together with the exercise price, to the Secretary
of the Company, or to such other person as the Company may designate, during regular business hours, together with such additional
documents as the Company may then require.

 

(b)         By exercising
your Option you agree that, as a condition to any exercise of your Option, the Company may require you to enter into an arrangement
providing for the payment by you to the Company of any tax withholding obligation of the Company arising by reason of (1) the exercise
of your Option, (2) the lapse of any substantial risk of forfeiture to which the shares of Common Stock are subject at the time
of exercise, or (3) the disposition of shares of Common Stock acquired upon such exercise.

 

(c)         If your
option is an Incentive Stock Option, by exercising your Option you agree that you will notify the Company in writing within fifteen
(15) days after the date of any disposition of any of the shares of the Common Stock issued upon exercise of your Option that occurs
within two (2) years after the date of your option grant or within one (1) year after such shares of Common Stock are transferred
upon exercise of your Option.

 

    	4

    	 

    

 

10.         Transferability.
Your Option is not transferable, except by will or by the laws of descent and distribution, and is exercisable during your life
only by you. Notwithstanding the foregoing, by delivering written notice to the Company, in a form satisfactory to the Company,
you may designate a third party who, in the event of your death, shall thereafter be entitled to exercise your Option. In addition,
if permitted by the Company you may transfer your Option to a trust if you are considered to be the sole beneficial owner (determined
under Section 671 of the Code and applicable state law) while the Option is held in the trust, provided that you and the trustee
enter into a transfer and other agreements required by the Company.

 

11.         Right
of Repurchase. To the extent provided in the Company’s bylaws in effect at such time the Company elects to exercise
its right, the Company shall have the right to repurchase all or any part of the shares of Common Stock you acquire pursuant to
the exercise of your Option.

 

12.         Option
not a Service Contract. Your Option is not an employment or service contract, and nothing in your option shall be deemed
to create in any way whatsoever any obligation on your part to continue in the employ of the Company or an Affiliate, or of the
Company or an Affiliate to continue your employment. In addition, nothing in your Option shall obligate the Company or an Affiliate,
their respective stockholders, Boards of Directors, Officers or Employees to continue any relationship that you might have as a
Director or Consultant for the Company or an Affiliate.

 

13.         Withholding
Obligations.

 

(a)         At the
time you exercise your Option, in whole or in part, or at any time thereafter as requested by the Company, you hereby authorize
withholding from payroll and any other amounts payable to you, and otherwise agree to make adequate provision for (including by
means of a “cashless exercise” pursuant to a program developed under Regulation T as promulgated by the Federal Reserve
Board to the extent permitted by the Company), any sums required to satisfy the federal, state, local and foreign tax withholding
obligations of the Company or an Affiliate, if any, which arise in connection with the exercise of your Option.

 

(b)         Upon your
request and subject to approval by the Company, in its sole discretion, and compliance with any applicable legal conditions or
restrictions, the Company may withhold from fully vested shares of Common Stock otherwise issuable to you upon the exercise of
your Option a number of whole shares of Common Stock having a Fair Market Value, determined by the Company as of the date of exercise,
not in excess of the minimum amount of tax required to be withheld by law (or such lower amount as may be necessary to avoid classification
of your Option as a liability for financial accounting purposes). If the date of determination of any tax withholding obligation
is deferred to a date later than the date of exercise of your Option, share withholding pursuant to the preceding sentence shall
not be permitted unless you make a proper and timely election under Section 83(b) of the Code, covering the aggregate number of
shares of Common Stock acquired upon such exercise with respect to which such determination is otherwise deferred, to accelerate
the determination of such tax withholding obligation to the date of exercise of your Option. Notwithstanding the filing of such
election, shares of Common Stock shall be withheld solely from fully vested shares of Common Stock determined as of the date of
exercise of your Option that are otherwise issuable to you upon such exercise. Any adverse consequences to you arising in connection
with such share withholding procedure shall be your sole responsibility.

 

    	5

    	 

    

 

(c)         You may
not exercise your Option unless the tax withholding obligations of the Company and/or any Affiliate are satisfied. Accordingly,
you may not be able to exercise your Option when desired even though your Option is vested, and the Company shall have no obligation
to issue a certificate for such shares of Common Stock or release such shares of Common Stock from any escrow provided for herein
unless such obligations are satisfied.

 

14.          Tax
Consequences. You hereby agree that the Company does not have a duty to design or administer the Plan or its other compensation
programs in a manner that minimizes your tax liabilities. You shall not make any claim against the Company, or any of its Officers,
Directors, Employees or Affiliates related to tax liabilities arising from your Option or your other compensation. In particular,
you acknowledge that this Option is exempt from Section 409A of the Code only if the exercise price per share specified in the
Grant Notice is at least equal to the “fair market value” per share of the Common Stock on the Date of Grant and there
is no other impermissible deferral of compensation associated with the Option. If at any time the Common Stock is not traded on
an established securities market, the Fair Market Value will be determined by the Board, perhaps in consultation with an independent
valuation firm retained by the Company. You acknowledge that there is no guarantee that the Internal Revenue Service will agree
with the valuation as determined by the Board, and you shall not make any claim against the Company, or any of its Officers, Directors,
Employees or Affiliates in the event that the Internal Revenue Service asserts that the valuation determined by the Board is less
than the “fair market value” as subsequently determined by the Internal Revenue Service.

 

15.         Notices.
Any notices provided for in your option or the Plan shall be given in writing and shall be deemed effectively given upon receipt
or, in the case of notices delivered by mail by the Company to you, five (5) days after deposit in the United States mail, postage
prepaid, addressed to you at the last address you provided to the Company.

 

16.         Electronic
Delivery. The Company may, in its sole discretion, decide to deliver any documents related to any Awards granted under
the Plan by electronic means or to request your consent to participate in the Plan by electronic means. You consent to receive
such documents by electronic delivery and agree to participate in the Plan through an online or electronic system established and
maintained by the Company or another third party designated by the Company, and such consent shall remain in effect throughout
your term of employment or service with the Company and thereafter until withdrawn in writing by you.

 

    	6

    	 

    

 

17.         Data
Privacy. You consent to the collection, use and transfer, in electronic or other form, of personal data as described
in this Option for the exclusive purpose of implementing, administering and managing your participation in the Plan. You acknowledge
that the Company holds certain personal information about you, including, but not limited to, name, home address and telephone
number, date of birth, social security number or other identification number, salary, nationality, job title, details of all Options
or any other entitlement to shares of stock awarded, cancelled, exercised, vested or unvested, for the purpose of implementing,
administering and managing the Plan (the “Data”). You acknowledge that Data may be transferred to any third parties
assisting in the implementation, administration and management of the Plan and that these recipients may be located in jurisdictions
that may have different data privacy laws and protections, and you authorize the recipients to receive, possess, use, retain and
transfer the Data, in electronic or other form, for the purposes of implementing, administering and managing the Plan, including
any requisite transfer of such Data as may be required to a broker or other third party with whom you or the Company may elect
to deposit any shares of stock acquired upon exercise of the Option.

 

18.         Governing
Plan Document. Your Option is subject to all the provisions of the Plan, the provisions of which are hereby made a part
of your option, and is further subject to all interpretations, amendments, rules and regulations, which may from time to time be
promulgated and adopted pursuant to the Plan. In the event of any conflict between the provisions of your Option and those of the
Plan, the provisions of the Plan shall control.

 

    	7Exhibit 10.1

 

MASTER SUPPLY & SERVICES CONTRACT

 

This Master Supply and Services Contract
(the “Contract”) is made on 2nd December, 2013 (“Effective Date”) between Pfizer Inc.
(“Pfizer”) with an address at 235 E. 42 Street, New York, NY 10017-5755, and Champions Oncology, Inc., with
an address at One University Plaza, Suite 307, Hackensack, NJ 07601 (“Company/You/Your”). Pfizer and Company each shall
be referred to herein as a “Party” and together as “Parties”.

 

WHEREAS: Pfizer wishes to acquire Patient
Derived Xenograft (PDX) mouse models (“Models”) from Company as described in Schedule A hereto; and

 

WHEREAS: Pursuant to future purchase orders,
Company may additionally provide biological services, including, but not limited, to in vitro and in vivo pharmacology
services and testing of biological ‘Samples’ (e.g., blood, urine, tissue, saliva, etc.) to Pfizer.

 

NOW, THEREFORE, the Parties agree that
the provision of Models and Services to Pfizer shall be established undertaken according to the following terms and conditions:

 

		1.	DEFINITIONS

 

		1.1	“Acceptance” shall mean Pfizer’s acceptance of the Products delivered
by Company and shall occur (a) on delivery where no acceptance test process has been specified by Pfizer or (b) in accordance with
mutually agreed upon guidelines within this Contract or agreed and documented elsewhere.

 

		1.2	“Affiliates” shall mean all companies which directly or indirectly control,
are controlled by or are under the common control with the relevant Party.

 

		1.3	“Animals” shall mean live, research Models.

 

		1.4	“Background Intellectual Property” shall mean Intellectual Property in existence
as of the Effective Date and Controlled by a Party.

 

		1.5	“Control or Controlled or Controlling” shall mean, with respect to Intellectual
Property, a Party (i) owns or (ii) has a license and has the ability to use and/or grant a license or sublicenses (as applicable)
to use such without violating the rights of any third party.

 

 

Confidential treatment has been requested
for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are
designated as ***. A complete version of this exhibit has been filed with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Act of 1934, as amended.

    	1

    	 

    

 

 

		1.6	“Force Majeure” shall mean any act of God, fire, natural disaster, unavailability
of essential materials, accident, act of government, or an act that is beyond the reasonable control of either Party and prohibits
performance hereunder.

 

		1.7	“Intellectual Property” shall mean any information, ideas, concepts, discoveries,
inventions, developments, know how, trade secrets, techniques, methodologies, modifications, innovations, improvements, writings,
documentation, data, know-how, material, composition of matter, method, process, product, biological material or other tangible
or intangible property, regardless of whether such property is patentable or not, or regardless of whether such property is protectable
through trademark or copyright, including without limitation, any foreign or domestic (i) patent right together with any extension,
registration, reissue, reexamination or renewal thereof, and any pending application, including any continuation, divisional, or
continuation in part thereof for any of the foregoing; (ii) trademark; or (iii) copyright.

 

		1.8	“Products” shall mean Company’s Models identified in Schedule A, as may
be updated from time to time by mutual agreement, or identified in any Purchase or Work Order.

 

		1.9	“Purchase Order” or “P.O.” shall mean written purchase orders
or work orders from Pfizer to Company for Services or Products. The terms and conditions of this contract will take precedence
over any printed Purchase Order terms and conditions.

 

		1.10	“Services” shall mean services provided by or on behalf of Company to Pfizer
to perform research services as directed by Pfizer and agreed upon by Company, which may include the use of Company’s own
methods and/or processes. No Services are provided by Company hereunder except as set forth in an accepted P.O.

 

		1.11	“Site” shall mean the Pfizer location where the Products will be provided to
Pfizer, as referred to in a Purchase Order or in Schedule A.

 

		1.12	“Specifications” means the specifications and other relevant characteristics
of a Product as defined in Schedule A or of Services as defined in a Purchase Order or other document agreed upon between Pfizer
and Company.

 

		2.	SCOPE

 

Company will
provide Products as set forth in Schedule A. From time to time during the term of this Contract, Pfizer may request and Company
shall provide Products or Services pursuant to the terms and conditions of this Contract; provided, however, that Pfizer shall
have no obligation to obtain any Products or Services from Company and Company shall have no obligation to provide Products and
Services other than that stated within Schedule A and pursuant to authorized Purchase Orders delivered to and accepted by Company.

 

Confidential treatment has been requested
for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are
designated as ***. A complete version of this exhibit has been filed with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Act of 1934, as amended.

    	2

    	 

    

 

 

Any Affiliate
of Pfizer may issue Purchase Orders under this Contract and will be deemed a Party to this Contract with respect to such orders.
Pfizer shall be liable for its Affiliates’ obligations under any P.O.

 

To the extent
there is any conflict or inconsistency between this Contract and Schedule A, Schedule A controls.

 

		3.	PERFORMANCE

 

You
must provide Products as stated in Schedule A in accordance with Specifications and perform any Services that may be described
in an accepted P.O. in accordance with stated instructions in the work order or Purchase Order. Without limiting any other legal
compliance requirement in this Contract, and notwithstanding the foregoing, You must provide any Products and perform any Services
under this Contract in compliance with all applicable laws and regulations, and You must maintain all licenses, certifications,
permits, and authorizations required to provide the Products or Services in the country in which they are performed. If You lose
an existing accreditation that is necessary for the performance of Services under a pending P.O. or the provision of Products
under Schedule A or are disqualified by any licensing or regulatory authority during the term of this Contract resulting in Your
inability to provide Products or Services, You will promptly notify Pfizer. This would be considered a material breach of the
Contract and Pfizer would be free to terminate the applicable P.O. or Schedule A as provided in the Term and Termination Section,
which contemplates early termination due to un-curable breach by a Party to this Contract.

 

		4.	OPERATING PROCEDURES & GUIDELINES

 

From time to
time, Pfizer may issue to You procedures or guidelines governing Your conduct of Services for Pfizer. If You accept any Purchase
Order after receiving such procedures or guidelines You will be deemed to have accepted them and You must comply with them for
such Purchase Order.

 

		5.	SHIPPING

 

You must package,
insure, process through customs and ship any materials or Products to be delivered to Pfizer under this Schedule A. Without prejudice
to any other remedy, if Company breaches any of the terms of a Purchase Order, Pfizer shall permit Company to re-perform the Services
so that they conform with the applicable Purchase Order. If after a period of thirty (30) days Company has not cured the default,
Pfizer may reject the Services in whole or in part at Company’s cost within a reasonable time after delivery notwithstanding
prior payment. Pfizer will reimburse You for the cost of repeating the Services if the non-conformity is due to the failure
of a Pfizer assay method (but only if is established that You strictly followed the assay method instructions) or the quality of
materials supplied by Pfizer. Otherwise You will bear the cost of repeating the Services.

 

 

Confidential treatment has been requested
for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are
designated as ***. A complete version of this exhibit has been filed with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Act of 1934, as amended.

    	3

    	 

    

 

 

		6.	PAYMENT

 

All details
relating to the fee to be paid by Pfizer for Products and Services under this Contract, including timing, payment of taxes, invoicing
procedure, discounts and taxes will be set out in Schedule A or an applicable Purchase Order or another document referencing this
Contract and agreed by You and Pfizer. So that Pfizer can confirm that You have accurately invoiced Pfizer, You must maintain records
reflecting the accuracy of Your invoices for at least two years after completion of the relevant Services.

 

		7.	PFIZER MATERIALS

 

		(a)	All materials, products and documents (or the property
of Pfizer’s third party supplier or collaborator) Pfizer gives You will remain Pfizer's property (“Pfizer Materials”).
You may only use them to perform Services under a P.O. and must not destroy them or transfer them to another facility or third
party without Pfizer's written consent.

 

		(b)	Pfizer will insure any Pfizer Materials Pfizer gives
You. You will not be liable for loss or damage to them unless it is due to Your negligence or willful misconduct.

 

		8.	INTELLECTUAL PROPERTY

 

		(a)	Each Party shall retain all right, title and interest
in and to its Background Intellectual Property.

 

		(b)	Pfizer acknowledges and agrees that all intellectual
property rights in the Company Models and in any Company technology, intellectual property and know-how used to produce the Company
Models, will at all times remain vested in Company. Pfizer may utilize the Company Models without limitation in the course of
its research activities, development activities and in its commercialization of pharmaceutical products. All rights to any inventions
or discoveries which may utilize the Company Models will belong to Pfizer, unless such inventions or discoveries of necessity
incorporate and include the Company Models.

 

 

 

Confidential treatment has been requested
for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are
designated as ***. A complete version of this exhibit has been filed with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Act of 1934, as amended.

    	4

    	 

    

 

 

 

                                                              

	 	 	 

 

		(c)	Except to permit You to perform the Services under a
P.O., You are not granted any right in Pfizer's Intellectual Property (or any Intellectual Property of Pfizer’s third party
collaborator or supplier). Except as provided below, Pfizer is not granted any right in Your Intellectual Property.

 

		(d)	Pfizer will own all Intellectual Property you produce
in performance of Services under a P.O., including but not limited to biological and other material or product, or any data and
reports that you produce for Pfizer under a P.O. Pfizer will also own all materials and information, of any form, developed or
received from others by you, as a result of or relating to Services under a P.O., including any methodologies or assays you develop
at Pfizer’s request and cost, assay data, samples, reports or other materials arising out of the Services. Additionally,
Pfizer will own any discoveries or inventions, whether patentable or not, that arise out of your performance of the Services under
a P.O., except those discoveries or inventions that relate exclusively to Your Intellectual Property and do not rely on Pfizer
confidential information and/or Intellectual Property. You will promptly notify Pfizer of any such invention or discovery. Pfizer
may use such material or product, data, reports or material defined in this Section 8(d) as Pfizer sees fit in its research, development
and commercialization of pharmaceutical products.

 

		(e)	Intellectual Property owned by Pfizer pursuant to Section
8(d) shall collectively constitute “Work Product.” For Services consisting of laboratory analyses of samples as may
be described in a P.O., Work Product will include both the results of the testing of samples and associated reports (“Assay
Data”) and materials generated during testing, including tapes, printouts, data sheets, images, and the like (“Raw
Data”). Unless a different retention period is specified in the Purchase Order, You will retain both Assay Data and Raw
Data for six (6) months after termination of the applicable P.O. under which they were generated or as required by applicable
law or governmental regulation, whichever is longer, unless Pfizer authorizes, in writing, earlier destruction. You agree to notify
Pfizer before destroying those records at the end of the retention period and to provide Pfizer an opportunity to remove them
at Pfizer’s expense. You agree that Pfizer will own and have unrestricted free right to use Work Product for all purposes
without further obligation or payment to you. You hereby assign and will ensure that your directors, officers, employees, agents,
or representatives assign all rights in the Work Product, including copyright, to Pfizer. Subject to payment by Pfizer of all
expenses you incur in connection therewith, you further agree to execute all further documents and assignments and do all such
further things as may be reasonably necessary to protect Pfizer's title to the Work Product or to register Pfizer as the exclusive
owner of any applicable registrable rights. You will deliver Work Product to Pfizer at the times and in the form specified in
the applicable P.O. Unless otherwise specified by Pfizer, in writing, you will deliver any as-yet undelivered Work Product to
Pfizer within 30 days after completion of the Services or termination of the applicable P.O., whichever occurs first. No delivery
of information or materials to You by Pfizer or on Pfizer’s behalf or any provision of this Contract will be construed to
grant You any rights or license to use any Pfizer Intellectual Property other than as specified in this Intellectual Property
section or as necessary for You to comply with your obligations under a P.O. For the avoidance of doubt, other than materials
or Work Product commissioned by Pfizer pursuant to a P.O., any of Your materials, methodologies, processes, Standard Operating
Procedures, software, personnel information, or Intellectual Property used by You or supplied to Pfizer in connection with these
Services will remain Your property (“Your Property”).

 

 

Confidential treatment has been requested
for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are
designated as ***. A complete version of this exhibit has been filed with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Act of 1934, as amended.

    	5

    	 

    

 

 

		(f)	You grant Pfizer a non-exclusive license to use Your
Property as is required to give Pfizer full benefit of the Work Product resulting from a P.O., including the right to authorize
others, such as research collaborators, service providers, and reviewing regulatory agencies, to use Your Property in connection
with their use of Work Product.

 

		(g)	If Pfizer gives You Pfizer Materials or processes and
requires You to use these in the Services, then Pfizer will indemnify You against any third party claims that Your use of such
Pfizer Materials or processes in performance of the Services infringes a third party's intellectual property rights.

 

		9.	CONFIDENTIALITY

 

		(a)	As used in this Contract, the term “Confidential
Information” means any information, including, without limitation, any technical, scientific, trade, research, manufacturing,
marketing or supplier information, that may be disclosed by one Party (the “Disclosing Party”) to the other Party
(the “Receiving Party”), regardless of whether such information is specifically designated as confidential and regardless
of whether such information is in written, oral, electronic, or other form; provided, however, that Confidential
Information shall not include any information that: (i) is already known by the Receiving Party at the time of disclosure; (ii)
is generally available to the public or becomes publicly known through no wrongful act of the Receiving Party; (iii) is disclosed
to the Receiving Party by a third party having the legal right to disclose it; or (iv) is independently developed by the Receiving
Party without use of the Confidential Information.

 

		(b)	Notwithstanding any other provision of this Contract,
disclosure of Confidential Information shall not be prohibited to the extent required to comply with applicable laws or regulations,
or with a valid court or administrative order, provided that the Receiving Party: (i) promptly notifies the Disclosing Party in
writing of the existence, terms and circumstances of such required disclosure; (ii) consults with the Disclosing Party on the
advisability of taking legally available steps to resist or narrow such disclosure; and (iii) takes all reasonable and lawful
actions to so resist or narrow such disclosure and to obtain confidential treatment for any such disclosure.

 

		(c)	The Receiving Party agrees that it shall: (i) protect
the Confidential Information with the same degree of care as it normally uses to preserve and safeguard its own proprietary information
of like nature, but not less than a reasonable degree of care; (ii) use Confidential Information solely for purposes of performing
its obligations under this Contract, and (iii) disclose Confidential Information only on a need to know basis to effect the purposes
of this Contract and only to its employees, permitted subcontractors and agents who have undertaken an obligation of confidentiality
substantially similar to that contained herein.

 

 

Confidential treatment has been requested
for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are
designated as ***. A complete version of this exhibit has been filed with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Act of 1934, as amended.

    	6

    	 

    

 

 

 

		10.	ANIMAL WELFARE COMPLIANCE

 

Pfizer is very concerned about
the proper use of Animals by parties with whom it contracts. Pfizer has established an Animal Care and Use policy which reflects
its commitment that Animals used in research are treated humanely by Pfizer and the parties with whom it contracts. Accordingly,
in performing Your obligations under this Contract You must:

	 	 	 
		·	adhere to the principles of Pfizer Corporate Policy 901, by complying with the policy statement
set out as Schedule B to this Contract;

	 	 	 
		·	give to Pfizer any information Pfizer reasonably requests that relates to the Animal welfare aspects
of Your operations in connection with performing obligations under this Contract;

	 	 	 
		·	comply with the applicable laws and guidelines when performing obligations under this Contract
and indemnify Pfizer against any liability Pfizer incurs solely and directly as a result of Your failure to so comply;

	 	 	 
		·	notify Pfizer if, at any time while performing obligations under this Contract, You are not compliant
with the laws, guidelines and procedures and the non-compliance poses a significant threat to the welfare of Animals; and

	 	 	 
		·	promptly take corrective steps if, at any time while performing obligations under this Contract,
Your conduct does not comply with the applicable laws, guidelines or procedures.

 

 

 

Confidential treatment has been requested
for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are
designated as ***. A complete version of this exhibit has been filed with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Act of 1934, as amended.

    	7

    	 

    

 

 

 

	
	 
	 
		11.	HUMAN TISSUE AND INFORMED CONSENT
	 

		(a)	Under this Contract, both Parties may provide cells,
cell cultures, tissues, genetic information or modified Animals containing such cells, cell cultures, tissues or genetic information
which are derived from human tissue (“Human Material”). Each Party retains all right, title and interest in and to
its Human Material. Any provision of Company Human Material will be pursuant to a limited license as set forth in Schedule A.

 

		(b)	The providing Party represents that Material provided
pursuant to this Contract will conform to the overall description, features, function and specifications set forth in the Schedule
A.  Furthermore, both Parties represent and warrant:

 

		(i)	As necessary, they have complied with all applicable
law in the collection and handling of the Material.

 

		(ii)	To the extent required by law, collection of the Material
was approved by an Institutional Review Board (“IRB”) that complies with all applicable governmental regulations for
such a body.

 

		(iii)	To the extent required by law, an IRB-approved informed
consent form (“ICF”) compliant with all applicable laws, regulations and government guidelines was signed by and obtained
from each donor (or the tissue from which the Material were derived) prior to donation in respect of each donation of Material
(“Informed Consent”).

 

		(iv)	The providing Party has legal right and title to the
Material and has the legal right to provide the Material and is not thereby infringing on the property rights or breaching the
contractual rights of any third party.

 

		(v)	To the extent required by law, uses of the Material described
in Schedule A are within the scope of and consistent with ethical approval policies, the Informed Consent, and the IRB’s
approval.

 

 

Confidential treatment has been requested
for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are
designated as ***. A complete version of this exhibit has been filed with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Act of 1934, as amended.

    	8

    	 

    

 

 

		12.	EH&S COMPLIANCE

 

It is very
important to Pfizer that its contractors comply in all respects with applicable environmental, health and safety laws and any related
guidelines or procedures Pfizer gives You. Accordingly, in performing this Contract You must:

 

		(a)	Give to Pfizer any information Pfizer reasonably requests
that relates to the environmental, health and safety aspects of Your operations, but solely to the extent it involves performance
of Your obligations under this Contract.

 

		(b)	Comply with the applicable laws and guidelines when performing
obligations under this Contract and indemnify Pfizer against any liability Pfizer incurs solely and directly as a result of Your
failure to so comply.

 

		(c)	Notify Pfizer if, at any time when performing obligations
under this Contract, You are not compliant with the laws, guidelines and procedures and the non-compliance poses a significant
threat to the environment or health and safety.

 

		(d)	Promptly take corrective steps if, at any time, Your
conduct of Services does not comply with the applicable laws, guidelines or procedures.

 

		(e)	Pfizer will give You all existing or generated environmental
and health and safety information for the starting material as described in the Purchase Order.

 

		13.	RELATIONSHIP OF THE PARTIES

 

		(a)	The relationship of the Parties is that of an independent
contractor. Neither Party’s employees have any right to receive compensation from the other Party or participate in the
other Party’s benefit plans. Each Party is solely responsible for all liabilities, costs and all other aspects of its staff's
employment.

 

		(b)	Neither Party has the power to act on the other Party’s
behalf or bind the other Party in any way, and each Party shall ensure that its employees do not represent to any third party
that he/she has such power.

 

		14.	SUBCONTRACTING

 

You must not
use subcontractors to perform Services under this Contract without Pfizer's written permission. If Pfizer gives permission, You
will be responsible for the subcontractor's performance and compliance with this Contract.

 

		15.	INSURANCE

 

Company will carry and maintain, at its own expense,
insurance coverage of the kind and with liability limits appropriate to the circumstances to protect itself and Pfizer against
any claims or liabilities that may arise from Company’s provision of Products and performance of Services. On written request
by Pfizer, Company will provide Pfizer with documentation of such insurance coverage Company will promptly notify Pfizer if it
is unable to obtain appropriate insurance coverage or if its coverage is canceled or unable to be renewed. Failure to maintain
adequate insurance coverage does not relieve or reduce Company liability under this Contract.

 

 

 

Confidential treatment has been requested
for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are
designated as ***. A complete version of this exhibit has been filed with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Act of 1934, as amended.

    	9

    	 

    

		a.	Worker's Compensation. As required by law.

		b.	Voluntary Compensation. Covering all employees
not subject to applicable Worker’s Compensation law at the coverage that would be required for Worker’s Compensation.

 

		c.	Employer's Liability. $1,000,000

		d.	Commercial General Liability. $2,000,000 per occurrence

 

		e.	Umbrella Liability. $5,000,000 per occurrence

 

Professional
Errors and Omissions. $5,000,000 per occurrence. Coverage must be maintained for at least five (5) years after the Term of
this Contract.

 

		16.	INDEMNIFICATION

 

		(a)	Pfizer will indemnify
You and Your officers, directors, shareholders, employees, agents and representatives against any third party claim arising from
Pfizer's: (i) breach of this Contract, Schedule A or any P.O.; (ii) use of materials, Products or Services supplied under, and
meeting the specifications and other requirements of, this Contract, Schedule A or any P.O.; or (iii) negligence or willful misconduct.
You must give Pfizer prompt written notice of such claims, permit Pfizer to control defense of the claim and give Pfizer, at Pfizer's
expense, reasonable assistance in defense of the claim. The indemnity will not apply if the claim arises directly from Your, or
any indemnified person's, negligence, willful misconduct or breach of this Contract, Schedule A or any P.O.

 

		(b)	You will indemnify
Pfizer and Pfizer’s officers, directors, shareholders, employees, agents and representatives against any third party claim:
(i) arising from Your breach of this Contract, Schedule A or any P.O.; (ii) alleging that the Products and/or Services as provided
under this Contract, Schedule A or any P.O. infringe or violate any patent, copyright, trademark, trade secret or other proprietary
right of a third party, provided, that You will not be obligated to indemnify to the extent a claim for infringement arises from
Pfizer’s (x) modification of the Product or Service, (y) use of the Product or Service inconsistent with the terms under
which they were provided to Pfizer, or (z) combination of the Product or Service with other products or services not provided
by You; or (iii) from Your negligence or willful misconduct in performance of Services, provided, that You will not be obligated
to indemnify if Your performance of Services was in compliance with Pfizer’s instructions. Pfizer must give You prompt written
notice of such claims, permit You to control defense of the claim and give You, at Your expense, reasonable assistance in defense
of the claim. The indemnity will not apply if the claim arises directly from Pfizer’s, or any indemnified person's, negligence,
willful misconduct or breach of this Contract, Schedule A or any P.O.

 

 

 

Confidential treatment has been requested
for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are
designated as ***. A complete version of this exhibit has been filed with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Act of 1934, as amended.

    	10

    	 

    

 

 

		(c)	If the Products and/or Services performed under this
Contract, Schedule A or any P.O. are deemed by a court of competent jurisdiction to have infringed a third party’s proprietary
right (and such infringement did not arise from Pfizer’s (x) modification of the Product or Service, (y) use of the Product
or Service inconsistent with the terms under which they were provided to Pfizer, or (z) combination of the Product or Service
with other products or services not provided by Company), then, at Your expense and at Your election:

 

		(i)	You will procure for Pfizer the past right to use and
the future right to continue to use the Products and/or Services;

 

		(ii)	You will replace or modify the Products and/or Services
to make such non-infringing, provided that substantially the same function is performed by the replacement or modified Products
and/or Services; or

 

		(iii)	If the past and future rights to use cannot be procured
or the Products and/or Services cannot be replaced or modified then You shall accept the return of the applicable Products and/or
Services and reimburse Pfizer for the unamortized fee for the Products and/or Services (original fee or Products amortized over
five years, on a straight-line basis).

 

		17.	LIMITATION OF LIABILITY

 

Neither Party
will be liable to the other under this Contract (or Schedule A or any P.O.), whether in tort, contract or otherwise, for any indirect
or consequential losses.

 

		18.	TERM AND TERMINATION

 

		(a)	This Contract will continue until terminated, or replaced,
or it expires on December 31, 2015. Any Products or Services delivered under a Purchase Order placed prior to the expiry of the
term of this Contract will continue to be governed by this Contract until their completion or unless and until any such Purchase
Orders are themselves terminated pursuant to this Contract. Pfizer may terminate any Purchase Order for Services or this Contract
without cause by giving You 30 days’ written notice. Pfizer’s only obligation will be to pay You for Products delivered
or Services completed, and non-cancelable expenses You have incurred at Pfizer's request, prior to termination. You must return
to Pfizer the balance of any payments made by Pfizer in excess of this obligation. Non-cancelable expenses are those expenses
that You cannot reasonably avoid or deploy for the benefit of other operations. They will not include staff costs but may include
raw materials. Pfizer and You will negotiate the amount of any such expenses in good faith. But, the amount plus any other payments
made by Pfizer under a Purchase Order may not exceed the total price of the Purchase Order.

 

 

 

Confidential treatment has been requested
for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are
designated as ***. A complete version of this exhibit has been filed with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Act of 1934, as amended.

    	11

    	 

    

 

 

		(b)	If either Party breaches this Contract (or Schedule A
or any P.O.), the other may terminate it if the breaching Party does not cure the breach within 30 days of written notice. Termination
will be without prejudice to any rights which may have accrued to either Party before termination.

 

		(c)	On termination of this Contract for any reason each Party
must return to the other Party, at its own expense, all materials, laboratory notebooks, other documents or confidential information
belonging to the other Party. If any information or documents are not in a returnable form, a Party must delete or render them
unreadable if practical; otherwise the Party must clearly mark them as the other Party’s confidential information, if practical.

 

		(d)	The termination or expiration of this Contract, Schedule
A or any Purchase Order under this Contract shall not affect the survival and continuing validity of Sections 8-9, 13, 16-19 and
21 of the Contract.

 

		19.	PUBLICITY

 

Neither You
nor Pfizer may publicize this Contract without the other's permission, except that a Party may disclose to the extent necessary
in the reasonable opinion of such Party’s legal counsel, to comply with applicable Law, including the rules and regulations
promulgated by the United States Securities and Exchange Commission or any equivalent governmental agency in any country in the
Territory, or any securities exchange rules. Before disclosing this Agreement or any of the terms hereof pursuant to this Section
19, the Parties will use reasonable efforts to consult with one another on the terms of this Agreement to be redacted in making
any such disclosure, with the disclosing Party providing as much advanced notice as is feasible under the circumstances, and giving
consideration to the comments of the other Party. Further, if a Party discloses this Agreement or any of the terms hereof in accordance
with this Section 19, such Party will, at its own expense, use reasonable efforts to seek such confidential treatment of confidential
portions of this Agreement and such other terms, as may be reasonably requested by the other Party. Neither Party may use the other
Party’s name in connection with any form of promotion without such Party’s prior written permission.

 

 

 

Confidential treatment has been requested
for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are
designated as ***. A complete version of this exhibit has been filed with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Act of 1934, as amended.

    	12

    	 

    

 

 

		20.	ETHICAL BUSINESS CONDUCT

 

Further, it
is very important to Pfizer that You comply with all applicable legal requirements and guidelines prohibiting unfair business practices.
Accordingly, You warrant that You are licensed, registered, or otherwise qualified under local law, regulations, policies, and
administrative requirements to do business. You further warrant that You have, to the extent required by applicable law, obtained
any licenses or completed any registrations required to provide the Services that are the subject of this Contract.

 

		21.	AUDITS

 

		(a)	To verify your compliance with this contract, Pfizer
may audit you upon giving you reasonable notice. Any audit will include the right to inspect any facility being used by you for
the services and to inspect all relevant records. You must co-operate fully with Pfizer during any audits.

 

		(b)	Pfizer must keep confidential any information that we
obtain when we audit you and that you tell us is confidential. Pfizer may only use this information, and disclose it to its employees
and advisers, as necessary for Pfizer to exercise its rights under this contract. Pfizer must not disclose this information to
a third party. This restriction will end seven years after the relevant audit.

 

		22.	GENERAL

 

		(a)	Assignment. Either Party may assign, in whole or in part,
its rights and transfer, in whole or in part, its obligations under this Contract to any of its Affiliates without the other Party’s
consent. Otherwise, neither Party may assign any of its rights or transfer any of its obligations under this Contract without
the other Party's prior written permission. Any assignment without such permission shall be void.

 

		(b)	Notices. All notices will be in writing and sent by certified
mail, return receipt requested, courier, or facsimile. Notices will be deemed given on the date they are received. Notices to
Pfizer must be sent to the address noted on the signature page and marked for the attention of President, WRD with a copy to General
Counsel, WRD. Notices to You must be sent to the address noted on the signature page and marked for the attention of CEO with
a copy to General Counsel.

 

 

 

Confidential treatment has been requested
for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are
designated as ***. A complete version of this exhibit has been filed with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Act of 1934, as amended.

    	13

    	 

    

 

 

		(c)	Severability. If any provision of this Contract is invalid
or is unenforceable, the Parties intend that the remainder of the Contract will be unaffected.

 

		(d)	Waiver. A Party's compliance with the terms of this Contract
may only be waived by written notice from the other Party. Unless stated otherwise a waiver will not be deemed an ongoing waiver.
Any delay or failure of a Party to require performance of a term of this Contract will not prevent the Party from enforcing the
term later.

 

		(e)	Force Majeure. A Party will not be in breach or liable
for any failure of delay of its performance of this Contract caused by a Force Majeure event.

 

		(f)	Binding Effect. This Contract will be binding upon and
shall inure to the benefit of Pfizer and You, and Pfizer's and Your respective successors and permitted assigns.

 

		(g)	Governing Law. This Contract is to be construed and determined
under the laws of the State of New York.

 

 

[The remainder of this page is blank
and is followed by the signature page.]

 

 

Confidential treatment has been requested
for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are
designated as ***. A complete version of this exhibit has been filed with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Act of 1934, as amended.

    	14

    	 

    

 

 

 

AGREED:

 

	
        Champions Oncology, Inc.

         

         

        By:  /s/ Joel Ackerman          

        Name:
Joel Ackerman

        

        Title: CEO

        

        

        Date: December 6, 2103

         

        Address:

        Champions Oncology, Inc.

        One University Plaza 

        Suite 307

        Hackensack, NJ 07601
	
        Pfizer Inc.

         

         

        By:  /s/ Steven W. Adams          

        Name:
Steven W. Adams

        

        Title: Executive Director R&D and

Business Operations

         

        Date: December 6, 2013

         

        Address:

        Pfizer Inc.

        235 East 42nd Street

        New York, NY 10017

         

	

 	 

 

 

Confidential treatment has been requested
for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are
designated as ***. A complete version of this exhibit has been filed with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Act of 1934, as amended.

    	15

    	 

    

 

 

 

Schedule A

 

 

Scope of Supply

 

 

Provision of Patient Derived Xenograft (PDX) Mouse Models:

 

General Project Scope:

 

Pfizer and Champions will enter into a Patient Derived Xenograft
(PDX) Services Agreement. Champions will license to Pfizer *** TumorGraft Models under the license terms described herein and in
Section 8 of the Contract.

 

“Company Data” shall mean, data generated
and provided by Company with respect to a specific Model or Product, deidentified patient data, standard operating procedures,
animal treatment, sentinel testing, and characterization data associated therewith.

 

You will furnish Products identified in Schedule A to Pfizer
for the purpose of Pfizer’s research and development evaluations. As between the Parties, Company shall retain ownership
of any Company Data already in existence at the time of transfer of the Models. Notwithstanding the foregoing, Pfizer may perform
its own characterization of Products (“Pfizer Data”) and Company shall have the right to use Pfizer Data as it sees
fit (subject to the duty of confidentiality with respect to Data originally delivered to Pfizer).

 

Champions grants Pfizer a limited, non-exclusive, non-transferable,
non-sublicenseable, license to use Champions’ standard operating procedures solely for the generation of Models including
but not limited to; efficacy analysis and biomarker studies.

 

Champions will provide technical support, and guarantee to ensure
Model growth in Pfizer labs as described herein.

 

For each Model that Pfizer selects, Champions will provide two
vials of Material. Champions will supply 5 fragments, 50-125 mm3 per fragment, (250-625 mm3 per vial at a
minimum in each vial).

 

Champions grants Pfizer a limited, non-exclusive, non-transferable,
non-sublicenseable, license under the Licensed Rights to perform the Licensed Activities. If in exercising the license granted
in the preceding sentence Pfizer is unable to generate four Animals with the two vials Champions provided, Champions will provide
two additional vials for that Model. If the two additional vials fails to yield four Animals, Champions will provide two additional
vials for that Model.

 

 

 

Confidential treatment has been requested
for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are
designated as ***. A complete version of this exhibit has been filed with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Act of 1934, as amended.

    	16

    	 

    

 

 

“Licensed Rights” means all intellectual property
and proprietary rights in and to Material owned by Champions.

 

“Licensed Activities” means efficacy analysis and
biomarker studies solely for Pfizer’s benefit.

 

At Pfizer’s sole discretion, Pfizer will provide Champions
with raw (non curated, primary molecular characterization data (RNA Seq or whole genome sequencing) when and if it is generated
by Pfizer, and Pfizer hereby grants Champions a non-exclusive, transferable, sublicenseable, perpetual license to use, copy, modify,
publish, display and distribute such data throughout the world in any media now known or hereafter developed.

 

Pfizer and Champions will seek opportunities for further Model
development and research collaboration.

 

Key Definitions:

P0 = Original patient sample

P1 = P0 patient sample passaged once in mice

P2 = Tumor tissues collected from the P1 mice passaged one additional
time in mice from thaw

P3 = Tumor tissues collected from the P2 mice passaged one additional
time in mice

 

Project Overview TumorGraft Model Licensing:

 

License Terms:

		·	License term is perpetual.

		·	Unlimited license to use Champions’ Models for PDX testing in Pfizer facilities

		·	Pfizer will be permitted to send tumor tissue to third parties for genomic testing or other in vitro assays, provided such
third parties use such tissue solely for Pfizer’s or Pfizer’s collaborators benefit.

		·	Champions will guarantee the viability of each Model as described herein. For Models that cannot be established in Pfizer’s
facility after reasonable effort and assistance by Champions, Champions will replace the Model with an alternative Model from the
Champions TumorBank.

 

Specific Criteria/Deliverables for established Models:

 

Deliverables for each TumorGraft PDX Model are:

Tumor material and data:

		·	At least 2 vials of frozen tumor fragments from lowest possible passage (ie P3 to P5), ready for implantation.

 

 

Confidential treatment has been requested
for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are
designated as ***. A complete version of this exhibit has been filed with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Act of 1934, as amended.

    	17

    	 

    

 

 

 

		·	Higher passage Models (ie P6 and above) will only be accepted if approved in advance by Pfizer.

		·	Patient and TumorGraft Model data if available:

		·	Patient diagnosis, treatment history and histology pictures of original tumor

		·	Patient demographics and medical history if available

		·	All existing molecular profiling data from the TumorGraft e.g. mutation and gene expression

		·	Historical data of TumorGraft sensitivity to chemotherapy or standard of care regimens where available

		·	Provision of Standard of Care data when available

		·	Growth curves of passaged Model

		·	Meets acceptable Pathogen testing criteria below:

		o	RADIL testing will be conducted on a sample that is directly antecedent or is in the same cohort as the sample provided to
Pfizer.

RADIL h-IMPACT
Profile I

 

PCR evaluation
for: EBV, HAdV, Hantaan, HCMV, Hepatitis A, Hepatitis B, Hepatitis C, HHV 6, HHV 8, HIV1, HIV2, HSV 1, HSV 2, HTLV 1, HTLV 2, Seoul,
Sin Nombre, VZV, Mycoplasma sp., LCMV 

 

RADIL Mouse IMPACT
I + C. Bovis

 

PCR evaluation
for: Corynebacterium bovis, Ectromelia, EDIM, Hantaan, K virus, LCMV, LDEV, MAD, mCMV, MHV, MNV, MPV, MTV, MVM, Mycoplasma sp.,
Polyoma, PVM, REO3, Sendai, TMEV, GDVII 

 

		·	QC requirements

		o	PDX Models must pass RADIL Pathogen testing (above) and free of mouse pathogens detailed on the exclusion list shown in Exhibit
A.

		·	Has demonstrated viability/take rate after having been frozen down after initial passage in mouse and therefore guaranteed
to grow from thaw without the addition of any biologics that might not comply with Pfizer’s biosafety requirements

		o	Champions will guarantee to swap or replace Models as soon as reasonably possible if they are not robust Models (ie, fail to
grow out from thaw)

 

Time Frame:

Established Models - *** Models established and ready for immediate
transfer after RADIL test and mouse pathogen testing, and no later than thirty (30) days from effective date of Contract

 

 

 

Confidential treatment has been requested
for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are
designated as ***. A complete version of this exhibit has been filed with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Act of 1934, as amended.

    	18

    	 

    

 

 

Data Reporting:

 

Pfizer and Champions will mutually decide on proper reporting
structure that would accompany transfer of each PDX Model.

 

Maintenance, Research Support and Technology Transfer:

 

Included in the license fee (except as stated otherwise herein):

		·	Champions will provide Pfizer with the know-how to grow and expand the licensed TumorGraft Models in their laboratories.

		·	Transfer of relevant SOPs of tumor initiation and propagation, including techniques specific to any tumor type.

		·	Training by Champions personnel on the TumorGrafting process via; on site visit of Pfizer scientists to directly observe key
steps in the TumorGraft process, such as processing and implantation of the primary tumor, and propagation of tumors, including
cryopreservation, Champions will offer annual updates of SOPs and additional support and training to ensure Pfizer can maximize
the utility of these Models.

 

Other critical business considerations:

 

		1.	Freedom to Operate (FTO):

 

Pfizer may use and run all transferred Models in-house
at Pfizer and with any Pfizer Affiliate.

 

Pfizer may use and run all transferred Models with
CROs provided, that no data about the Models can be shared with such CROs. Pfizer will promptly notify Champions which models where
transferred and to which CROs they were transferred. Pfizer shall cause CROs to comply with all license and confidentiality terms
and conditions and that any failure of the CRO to comply will be considered a breach by Pfizer.  Breach would give rise to
indemnity rights under Section 16(a). 

 

		2.	Additional In vivo Services:

 

Champions may do TumorGraft study work as directed
by Pfizer to complement and supplement the in-house PDX efforts of Pfizer. Fees for TumorGraft studies will be based on a standard
base fee per study mouse that will be reduced based on volume discounts and Pfizer’s license of Champions Models and potentially
increased for specific study designs that add to the cost and complexity of studies and will be agreed in advance between Pfizer
and Champions.

 

 

Confidential treatment has been requested
for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are
designated as ***. A complete version of this exhibit has been filed with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Act of 1934, as amended.

    	19

    	 

    

 

 

Commercial Terms:

 

Models to be Licensed:

 

Pfizer will license up to *** Models in 2013 as detailed below.
See below table for Model details by tumor type (Specific Models details to be provided by Pfizer). Pfizer may amend this list
through mutual agreement with Champions if required.

 

	Priority	Cancer	Not Treated	Pretreated	Unknown	Total
	1	Lung - NSCLC	***	***	***	***
	2	Colorectal	***	***	 	***
	3	Breast	***	***	***	***
	4	Ovarian	***	***	***	***
	5	Pancreatic	***	***	 	***
	6	Head & Neck	***	***	***	***
	7	Lung - SCLC	***	***	 	***
	8	Prostate	***	***	 	***
	9	To Be Determined	 	 	 	***
	 	 	***	***	***	***
	 	 	 	 	 	 
	Models from Champions = ***

 

Pfizer agrees to receive the Models listed above subject to
the license terms as stated herein, subject to the delivery and acceptance criteria described above at a fully inclusive, onetime
fee of $***/ PDX Model.

 

The all-inclusive fee for the deliverables (based on *** Models)
is $1,875,000. Payment will be adjusted on a pro-rata basis if *** Models are not deemed suitable by Pfizer.

 

For delivery of *** Model’s, the following payment schedule
will apply:

 

	Milestone	Payment Schedule	Payment Amount
	50% Upfront Payment	Upon Contract execution	$937,500
	Upon Delivery of all *** Models	On Delivery , no later than 13th Dec 2013	$937,500

 

 

 

Confidential treatment has been requested
for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are
designated as ***. A complete version of this exhibit has been filed with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Act of 1934, as amended.

    	20

    	 

    

 

 

Should
Pfizer wish to acquire any Models in excess of the *** Models, the cost per Model of $***/ PDX Model will apply for at least P3-P5
tumors as defined above.

Pfizer’s
Standard Purchase Order Payment terms will govern timing of payment following invoicing.

 

 

Exhibit A - Minimum Health Standards for Rodents- Exclusion
List for Entry to Pfizer Research Facilities

 

The Exclusion List is a list of pathogenic organisms that are
unacceptable to Pfizer research programs because of their potential to interfere with research. Generally, Animals testing positive
or potentially positive for these organisms will not be accepted for receipt onto the research site. If organisms on the list are
detected in the existing research Animal population, appropriate Comparative Medicine personnel will work to limit the spread of
the agent by instituting quarantine or depopulation procedures.

 

Exceptions to the policy of excluding Animals positive for these
organisms from the research site can be considered on a case-by-case basis. Approval for an exception must be made by appropriate
Comparative Medicine personnel and would include a specific plan for limiting the spread of the organism and minimizing the risk
to the research Animal population.

 

 

	Required negative test results to enter any Pfizer Research facility 
	Agent	Mouse	Rat	Hamster	Gerbil	Guinea Pig
	VIRUSES	 	 	 	 	 
	Mouse Hepatitis Virus (MHV)	X	 	 	 	 
	Minute Virus of Mice (MVM, MMV)	X	 	 	 	 
	Ectromelia Virus (ECTRO)	X	 	 	 	 
	Mouse  Pneumonitis Virus (K Virus)	X	 	 	 	 
	Polyoma Virus (POLY)	X	 	 	 	 
	Mouse Cytomegalovirus (MCMV)	X	 	 	 	 
	Epizootic Diarrhea of Infant Mice Virus (EDIM)	X	 	 	 	 

 

 

 

Confidential treatment has been requested
for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are
designated as ***. A complete version of this exhibit has been filed with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Act of 1934, as amended.

    	21

    	 

    

 

 

	Agent	Mouse	Rat	Hamster	Gerbil	Guinea Pig
	Mouse Thymic Virus (MTLV)	X	 	 	 	 
	Mouse Parvovirus (MPV)	X	 	 	 	 
	Lactate Dehydrogenase Elevating Virus (LDV)	X	 	 	 	 
	Mouse Norovirus	X	 	 	 	 
	Mouse Polio (Encephalomyelitis) Virus (TMEV, GDVII) or Rat Theiler’s-like Virus (RTV)	X	X 	 	 	 
	Lymphocytic Choriomeningitis Virus (LCMV)	X	X	X	X	X
	Sendai Virus	X	X	X	 	X
	Pneumonia Virus of Mice (PVM)	X	X	X	 	X
	Respiratory Enteric Virus (Reovirus) Type 3 (REO3)	X	X	X	 	X
	Hantaan Virus (HANT)	X	X	 	 	 
	Mouse Adenovirus (MAV1/FL, MAV2/K87)	X	X	 	 	 
	Kilham Rat Virus (KRV, RV)	 	X	 	 	 
	Toolan’s H-1 Virus (H-1)	 	X	 	 	 
	Rat Coronavirus/Sialodacryoadenitis Virus (RCV/SDAV)	 	X	 	 	 
	Rat Parvovirus (RPV)	 	X	 	 	 
	Guinea Pig Adenovirus (GAV)	 	 	 	 	X
	BACTERIA	 	 	 	 	 
	Mycoplasma pulmonis (MPUL)	X	X	X	X	X
	Bordetella bronchiseptica	X	X	X	X	X
	Streptococcus pneumoniae	X	X	X	X	X
	Pasteurella spp (e.g., P. multocida, P. pneumotropica)	X	X	 	 	 
	Encephalitozoon cuniculi (ECUN)	X	X	X	 	X
	Salmonella spp.	X	X	X	 	X
	Streptobacillus moniliformis	X	X	 	 	X

 

 

 

Confidential treatment has been requested
for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are
designated as ***. A complete version of this exhibit has been filed with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Act of 1934, as amended.

    	22

    	 

    

 

 

	Cilia-Associated Respiratory Bacillus (CARB)	X	X	 	 	 
	Corynebacterium kutscheri	X	X	 	 	 
	All Helicobacters, including hepaticus, bilis, muridarum, rodentium, and other species	X	X	X	 	X
	Citrobacter rodentium/freundii 4280	X	 	 	 	 
	Agent	Mouse	Rat	Hamster	Gerbil	Guinea Pig
	Campylobacter jejuni	 	 	 	 	 
	Campylobacter spp.	 	 	 	 	 
	Clostridium piliforme	X	X	 	X	X
	Streptococcus zooepidemicus	 	 	 	 	X
	OTHER ORGANISMS	 	 	 	 	 
	Major GI metazoan endoparasites (e.g., Syphacia, Aspiculuris, Rodentolepis)	X	X	X	X	X
	Major ectoparasites (e.g., Myocoptes, Polyplax, Myobia, Radfordia)	X	X	X	X	X
	Major enteric protozoa (e.g., Coccidia, Giardia, Spironucleus)	X	X	X	X	X
	Pneumocystis carinii (immunodeficient Animals only)	X	X	 	 	 
	Corynebacterium bovis (immunodeficient Animals only)	X	X	 	 	 

 

 

Confidential treatment has been requested
for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are
designated as ***. A complete version of this exhibit has been filed with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Act of 1934, as amended.

    	23

    	 

    

 

 

Schedule B - Animal Care and Use Policy

 

For as long as it remains necessary to
use Animals in biomedical research in the discovery, development
and evaluation of new medicines, You commit to maintaining high standards in the humane treatment of these Animals. You embrace
the principles known as the 3Rs of Animal research first proposed in 1959 by Russell and Burch
to describe the use of alternatives in Animal research. These are:

 

Replacement of Animal experiments
with non-Animal experiments such as mathematical models, computer simulations, and in vitro biological systems wherever
appropriate; and where Animals must be used -

 

Reduction of the numbers of Animals
used in each study, and of the number of studies involving Animals, to the absolute minimum necessary to obtain valid results and
achieve our research objectives; and

 

Refinement of procedures involving
Animals to minimize the potential for pain and distress.

 

 

In addition to the 3R’s, and to further
assure You maintain high standards for the Animals You use, You adopt the following guidelines:

 

·        
When Animal experimentation is necessary, great care is taken to choose the most appropriate Animal species for the research
and to optimize the study design to ensure that the results will be as meaningful as possible.

 

·        
All studies are carefully designed to gain the maximum information from the fewest number of Animals possible.

 

·        
Each proposed use of Animals is reviewed and approved by a panel of objective experts prior to performing any experiments
to ensure that the use of the Animals is consistent with sound scientific practices and ethical considerations.

 

·        
Your standards of Animal care and welfare meet or exceed those required by applicable local, national, or international
laws and regulations.

 

·        
Regularly monitor Your Animals for signs of ill health or distress and take prompt action wherever appropriate. You make
veterinary care available to Your Animals at all times.

 

·        
Your veterinarians and scientists evaluate every proposed Animal procedure with
an emphasis on eliminating or minimizing any potential for pain or distress which may be experienced by the Animals.

 

·        
You train all involved in the care, welfare and use of Animals in Your business
to ensure (a) that they are competent in the care of the Animals and in the procedures required to complete the proposed work;
(b) that they are aware of the ethical issues involved in the use of Animals; and (c) that they
demonstrate respect and humane treatment towards the Animals in their care.

 

 

 

Confidential treatment has been requested
for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are
designated as ***. A complete version of this exhibit has been filed with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Act of 1934, as amended.

    	24

    	 

    

 

 

Schedule C - Information Protection
Requirements

 

The requirements that follow apply to Pfizer Confidential Information,
as that term is defined in the Contract. This includes any Personal Data that is provided by Pfizer or collected on Pfizer’s
behalf. . Pfizer may review compliance with these requirements during onsite inspections or audits. Nothing herein shall obligate
Champions to take or allow any action that reveals Champions’ trade secrets, violate any agreement with a third party, or
impose an unreasonable and undue burden on Champions’ resources.

 

	Pfizer Ref #	

Topic	

Requirement
	 	 	When providing Services to Pfizer, Company will
	1.1	Privacy/Personal Data/Confidentiality	have a storage and transit  policy and control measures for Confidential Information (all forms) that will reasonably protect it from damage, loss, or unauthorized disclosure, 
	2.1	Access Control	implement commercially reasonable policies and procedures regarding the protection from unauthorized and unnecessary access to systems that contain Confidential Information,
	3.1	Physical Security	Implement commercially reasonable physical security in place restricting access to its facilities, network, or, computer systems (hardware) that contain Confidential Information, 
	4.1	Quality Systems	have quality systems** and processes in place to address (a) the integrity of data obtained from or generated on behalf of Pfizer and (b) compliance with applicable regulations,
	4.2	Quality Systems	have adequate quality systems* to manage the development, operation, and documentation of computerized systems used for creation and management of Confidential Information,
	5.1	Record Protection	have in place commercially reasonable business continuity processes and procedures,
	5.2	Record Protection	Use commercially reasonable means to protect against computerized virus outbreaks,
	5.3	Record Protection	notify Pfizer promptly if any Confidential Information in its possession becomes at risk of loss or corruption for any reason, and
	6.1	Delegation to Third Parties	on request, if permitted by third-party confidentiality restrictions, provide Pfizer access to the relevant sections of contracts relating to delegation of information management responsibilities for Confidential Information to a third party.  

 

* system
to direct and control an organization with regards to quality management and control processes and procedures

 

 

 

Confidential treatment has been requested
for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are
designated as ***. A complete version of this exhibit has been filed with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Act of 1934, as amended.

    	25

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00228-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00228-of-00352.parquet"}]]